top of page
Discover the Latest in Biomedical Research Innovation
Search


Two-Way ANOVA in SPSS: A Step-by-Step SOP for Interaction Plots and Simple Effects
A two-way ANOVA in SPSS takes one menu and five dialogs, and three of their defaults can quietly mislead you: the Post Hoc button compares the wrong means after an interaction, the right comparisons are uncorrected unless you change a dropdown, and the unequal-variance tests never run in a two-factor model. This SOP runs the analysis correctly, from data entry to a reportable result.
Oct 126 min read


The Delta Delta Ct Method Demystified: Calculating Relative Gene Expression Step by Step
The delta delta Ct method turns two Cq values per sample into a fold change in a minute of arithmetic. The two mistakes it hides take longer to spot: efficiency that is not quite 100%, which inflates your biggest results, and statistics run on fold changes instead of Cq values. This SOP runs from raw Cq to a fold change with a correct, asymmetric confidence interval.
Oct 76 min read


Two-Way ANOVA vs Repeated Measures ANOVA vs Mixed-Effects Models: Which One Fits Your Experiment?
If every measurement comes from a different animal, use ordinary two-way ANOVA. If the same animals are measured at every time point with nothing missing, use repeated measures ANOVA. If even one value is missing, use a mixed-effects model. Here is how to match the model to your design, what each mistake costs, and how to set each one up in GraphPad Prism.
Oct 55 min read


Reference Genes for qPCR: How to Choose and Validate Them (Beyond Just Using GAPDH)
If your treatment raises GAPDH by half, every target you normalize to it looks a third lower, even if nothing changed. Few labs check: studies use 1.2 reference genes on average, and only 15% test a panel first. This guide covers choosing candidates from different pathways, validating them with geNorm and NormFinder, and what MIQE 2.0 now asks you to report.
Sep 305 min read


Two-Way ANOVA Interaction Effects: Step-by-Step SOP for Testing Your Treatment Between Groups
Your drug works in wild-type mice and not in the knockout, so the effect depends on the gene. That conclusion does not follow, and in one major review of top journals, half the papers that needed the right test got it wrong. This two-way ANOVA interaction SOP runs the correct analysis in GraphPad Prism, from data entry to a reportable result, with a worked example in which the naive reading and the right answer disagree.
Sep 287 min read


CLYTE's Sophie 4.5 Is Here: A Smarter Model, a 3× Faster Regulatory Engine, and a Cleaner Way to Work
Sophie 4.5 is live. It keeps everything that made 4.0 work and sharpens what matters: the core chat is ~40% more intelligent at the same speed, and the Regulatory Architect is 3x faster, ~25% smarter, and now wired directly into the CFR database for more accurate device classification. The Visualizer and Analytics engines get intelligence and speed bumps, and a wave of UI/UX updates came straight from how people used 4.0. Here's everything new in CLYTE's Sophie 4.5.
Jul 134 min read


We Tricked ChatGPT, Gemini & Claude Into Approving a Non-Compliant FDA Submission. The Case for Non-Sycophant Regulatory AI!
A former FDA reviewer ran a test for us. He took a real problem — a device with an endotoxin level his team couldn't lower — and tried to bait four AIs into approving a workaround he knew was wrong. One by one, ChatGPT, Gemini, and Claude came around and told him to proceed. Sophie refused: it cited the guidelines, held the line when he pushed, and sent him to the FDA. In regulated work, an AI eager to agree is a liability. Here's what happened — plus a test you can run yours
Jun 2210 min read


Notes from NY Tech Week: What Anish Acharya and Shuo Wang Taught Us About Building AI Startups
We took notes at NY Tech Week 2026. In an a16z masterclass, Deel's Anish Acharya and Shuo Wang made the case that the most defensible AI is built where decisions carry liability — the ground a model can't own. IBM's Gary Cohn added the data-sovereignty argument for small, specialized, walled-off models. For an AI built for FDA-regulated biomedical research, that's the whole thesis. Here's what we took from the week — and the a16z session is now a podcast on our channel.
Jun 1510 min read
bottom of page
